Clinical Trials Logo
  1. Home
  2. Gonorrhea
  3. NCT03071510
  4. Details
NCT03071510 Clinical Trial

Evaluation of the Atlas Genetics io® CTNG System

Gonorrhea Clinical Trial

— IO-CTNG  

Official title:
IO-CTNG: A Multi-Centre Evaluation of the Atlas Genetics io® CTNG System Used in Centralised and Point of Care Settings

Clinical Trial Details — Status: Completed

Administrative data
NCT number NCT03071510
Other study ID # MOB-VTP-001
Secondary ID
Status Completed
Phase
First received
Last updated
Start date May 18, 2017
Est. completion date August 30, 2019

Study information
Verified date April 2020
Source Binx Health Limited
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Atlas Genetics io® system results are compared with those obtained from comparator devices.

Description:

Results from the Atlas Genetics io® system are compared with a Composite Infection Status obtained from testing on three commonly used comparator devices.

This is a prospective, single-arm, multi-centre investigation enrolling up to 12,000 adult participants over 14 years of age who are undergoing testing for the presence of CT/NG.

Recruitment information / eligibility
Status Completed
Enrollment 7128
Est. completion date August 30, 2019
Est. primary completion date August 30, 2019
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 14 Years and older
Eligibility Inclusion Criteria:

1. Symptomatic and asymptomatic individuals =14 years of age

Exclusion Criteria:

1. Treatment with antibiotics known to be effective against Chlamydia trachomatis and/or Neisseria gonorrhoeae within the previous 4 weeks before inclusion in the study.

2. Unable to self-obtain a vaginal swab or urine sample of at least 30 mL

Study Design

Related Conditions & MeSH terms

Intervention

Device:
• Atlas Genetics io® system
Specimen Collection

Locations
Country Name City State
United States Johns Hopkins University Baltimore Maryland
United States University of Alabama Birmingham Alabama
United States University of North Carolina at Chapel Hill Chapel Hill North Carolina
United States Wake Forest Center for Reproductive Medicine Greensboro North Carolina
United States Planned Parenthood Gulf Coast Houston Texas
United States Indiana University Indianapolis Indiana
United States University of Mississippi Jackson Mississippi
United States AIDS Healthcare Foundation Los Angeles California
United States Louisiana State University New Orleans Louisiana
United States Planned Parenthood Southeastern Pennsylvania Philadelphia Pennsylvania

Sponsors (1)
Lead Sponsor Collaborator
Binx Health Limited

Country where clinical trial is conducted

United States, 

Outcome
Type Measure Description Time frame Safety issue
Primary Diagnostic Accuracy compared to positive Composite Infected Status from comparator devices The assessment of the diagnostic accuracy of the study device as compared to positive Composite Infected Status from comparator devices Up to 7 days
See also
  Status Clinical Trial Phase
Completed NCT01439503 - Safer Sex Program for Young African-American Men Phase 2
Completed NCT00381992 - Risk Assessment of Long-Haul Truck Drivers N/A
Completed NCT03294395 - New AntiBiotic Treatment Options for Uncomplicated Anogenital GOnorrhoea Phase 3
Not yet recruiting NCT06428643 - A Seek, Test, and Treat Intervention to Reduce Chlamydia Trachomatis Disparities N/A
Completed NCT03896776 - A Pragmatic Trial of Two Strategies for Implementing an Effective eHealth HIV Prevention Program (Keep It Up! 3.0) N/A
Completed NCT03718806 - Study to Investigate Effect of Food and Safety of a New Formulation of Zoliflodacin Phase 1
Completed NCT04010539 - A Study Evaluating Efficacy and Safety of Gepotidacin Compared With Ceftriaxone Plus Azithromycin in the Treatment of Uncomplicated Urogenital Gonorrhea Phase 3
Completed NCT00187902 - Evaluation of NAATs for Detection of C. Trachomatis and N. Gonorrhoeae From Pharynx, Rectum, Glans & Urethra of MSM N/A
Completed NCT00262106 - Trial to Evaluate PRO 2000/5 Gels for the Prevention of Vaginally Acquired HIV Infection Phase 3
Completed NCT00207506 - Lay Health Advisors for Sexually Transmitted Disease Prevention Phase 1/Phase 2
Completed NCT04553068 - Evaluation of EVO100 for Prevention of Urogenital Chlamydia Trachomatis and Neisseria Gonorrhoeae Infection Phase 3
Active, not recruiting NCT03959527 - Zoliflodacin in Uncomplicated Gonorrhoea Phase 3
Active, not recruiting NCT03980223 - Evaluation of Doxycycline Post-exposure Prophylaxis to Reduce Sexually Transmitted Infections in PrEP Users and HIV-infected Men Who Have Sex With Men Phase 4
Completed NCT01465607 - Implementation of an Efficacious Intervention for High Risk Women in Mexico N/A
Terminated NCT00120770 - Cellulose Sulfate (CS) Gel and HIV in Nigeria Phase 3
Completed NCT02391233 - Multimedia WORTH With Black Drug-Involved Women on Probation N/A
Recruiting NCT05766904 - Efficacy Trial on Meningococcal B Vaccine for Preventing Gonorrhea Infections Phase 3
Completed NCT04297436 - Gonococcal Vaccine Study in Key Populations in Kenya N/A
Completed NCT03098329 - Check it: A New Approach to Controlling Chlamydia Transmission in Young People N/A
Completed NCT01836445 - Keep It Up! 2.0: A Comparison of Two Online HIV Intervention Programs for Young Men Who Have Sex With Men N/A